MA53852A - Anticorps ciblant le cd137 et leurs méthodes d'utilisation - Google Patents
Anticorps ciblant le cd137 et leurs méthodes d'utilisationInfo
- Publication number
- MA53852A MA53852A MA053852A MA53852A MA53852A MA 53852 A MA53852 A MA 53852A MA 053852 A MA053852 A MA 053852A MA 53852 A MA53852 A MA 53852A MA 53852 A MA53852 A MA 53852A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- targetting
- antibodies
- antibodies targetting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18199334.6A EP3636320A1 (fr) | 2018-10-09 | 2018-10-09 | Anticorps dirigés contre cd137 et leurs procédés d'utilisation |
EP19166283 | 2019-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53852A true MA53852A (fr) | 2021-08-18 |
Family
ID=68208314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053852A MA53852A (fr) | 2018-10-09 | 2019-10-09 | Anticorps ciblant le cd137 et leurs méthodes d'utilisation |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210395379A1 (fr) |
EP (1) | EP3863717A1 (fr) |
JP (1) | JP2022512628A (fr) |
KR (1) | KR20210076907A (fr) |
CN (1) | CN112805068A (fr) |
AU (1) | AU2019358442A1 (fr) |
CA (1) | CA3112058A1 (fr) |
IL (1) | IL281767A (fr) |
MA (1) | MA53852A (fr) |
SG (1) | SG11202103503WA (fr) |
WO (1) | WO2020074584A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022532173A (ja) * | 2019-05-10 | 2022-07-13 | リビジェン バイオファーマ カンパニー リミテッド | ヒト化抗cd137抗体およびその使用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993011794A1 (fr) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
WO1998056915A2 (fr) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Polypeptides d'anticorps artificiels |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
CN1440812A (zh) * | 2002-02-27 | 2003-09-10 | 上海中信国健药业有限公司 | 一种使用cd137结合激动剂增强免疫应答的方法 |
EP1539237A4 (fr) | 2002-07-30 | 2006-05-24 | Bristol Myers Squibb Co | Anticorps humanises contre le 4-1bb humain |
PL1945666T3 (pl) * | 2005-10-21 | 2013-09-30 | Genzyme Corp | Przeciwciała o wzmocnionej aktywności zależnej od przeciwciał cytotoksyczności komórkowej, sposoby ich wytwarzania i zastosowanie |
DK2158220T3 (en) | 2007-06-26 | 2017-07-10 | F-Star Biotechnologische Forschungs- Und Entw M B H | Display of binders |
WO2010047830A2 (fr) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | Agent permettant le traitement du virus de l'hépatite c |
CA2810359C (fr) | 2010-09-09 | 2021-06-22 | Pfizer Inc. | Molecules de liaison 4-1bb |
KR102588377B1 (ko) * | 2014-11-14 | 2023-10-12 | 에프. 호프만-라 로슈 아게 | Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자 |
CA2989474C (fr) | 2015-06-15 | 2023-09-05 | Numab Innovation Ag | Format d'anticorps heterodimeres multispecifiques |
EA201990578A1 (ru) * | 2016-09-23 | 2019-10-31 | Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой | |
CN117752798A (zh) * | 2016-12-19 | 2024-03-26 | 豪夫迈·罗氏有限公司 | 用靶向性4-1bb(cd137)激动剂的组合疗法 |
-
2019
- 2019-10-09 EP EP19786325.1A patent/EP3863717A1/fr active Pending
- 2019-10-09 CA CA3112058A patent/CA3112058A1/fr active Pending
- 2019-10-09 MA MA053852A patent/MA53852A/fr unknown
- 2019-10-09 CN CN201980065887.3A patent/CN112805068A/zh active Pending
- 2019-10-09 WO PCT/EP2019/077368 patent/WO2020074584A1/fr unknown
- 2019-10-09 SG SG11202103503WA patent/SG11202103503WA/en unknown
- 2019-10-09 AU AU2019358442A patent/AU2019358442A1/en active Pending
- 2019-10-09 JP JP2021518965A patent/JP2022512628A/ja active Pending
- 2019-10-09 US US17/283,128 patent/US20210395379A1/en active Pending
- 2019-10-09 KR KR1020217010260A patent/KR20210076907A/ko unknown
-
2021
- 2021-03-24 IL IL281767A patent/IL281767A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210395379A1 (en) | 2021-12-23 |
KR20210076907A (ko) | 2021-06-24 |
CN112805068A (zh) | 2021-05-14 |
AU2019358442A1 (en) | 2021-03-25 |
CA3112058A1 (fr) | 2020-04-16 |
JP2022512628A (ja) | 2022-02-07 |
SG11202103503WA (en) | 2021-05-28 |
TW202035457A (zh) | 2020-10-01 |
IL281767A (en) | 2021-05-31 |
WO2020074584A1 (fr) | 2020-04-16 |
EP3863717A1 (fr) | 2021-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA50354A (fr) | Anticorps ciblant le cd137 et leurs méthodes d'utilisation | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA52459A (fr) | Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA54952A (fr) | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci | |
MA48595A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
MA56165A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
MA48462A (fr) | Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation | |
MA49288A (fr) | Reactifs particulaires oligomères et leurs méthodes d'utilisation | |
MA48852A (fr) | Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
MA50958A (fr) | Anticorps anti-apoc3 et leurs méthodes d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA53492A (fr) | Anticorps anti-cd33 et leurs méthodes d'utilisation | |
MA44081A (fr) | Anticorps anti-c5 et leurs procédés d'utilisation |